# Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication

> **NCT02557932** · PHASE3 · COMPLETED · sponsor: **National Cancer Center, Korea** · enrollment: 352 (actual)

## Conditions studied

- Helicobacter Pylori Infection
- Family History of Stomach Cancer

## Interventions

- **DRUG:** Standard triple therapy
- **DRUG:** Bismuth quadruple therapy

## Key facts

- **NCT ID:** NCT02557932
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2018-12
- **Final completion:** 2019-09-28
- **Target enrollment:** 352 (ACTUAL)
- **Last updated:** 2020-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02557932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02557932, "Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02557932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*